Magenta Therapeutics Top Management
MGTADelisted Stock | USD 0.82 0.03 3.80% |
Magenta Therapeutics employs about 67 people. The company is managed by 9 executives with a total tenure of roughly 157 years, averaging almost 17.0 years of service per executive, having 7.44 employees per reported executive. Analysis of Magenta Therapeutics' management performance can provide insight into the company performance.
Magenta |
Magenta Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2885) % which means that it has lost $0.2885 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6534) %, meaning that it created substantial loss on money invested by shareholders. Magenta Therapeutics' management efficiency ratios could be used to measure how well Magenta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Magenta Therapeutics Workforce Comparison
Magenta Therapeutics is regarded fifth in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 843. Magenta Therapeutics holds roughly 67.0 in number of employees claiming about 8% of equities under Health Care industry.
Magenta Therapeutics Notable Stakeholders
A Magenta Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Magenta Therapeutics often face trade-offs trying to please all of them. Magenta Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Magenta Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Caren Deardorf | Chief Officer | Profile | |
David Nichols | Chief Officer | Profile | |
Jason DPHIL | CEO, CoFounder | Profile | |
Catherine Monaghan | Head Operations | Profile | |
Lisa Olson | Head Officer | Profile | |
MBA JD | Chief Treasurer | Profile | |
Jim Haney | Director Relations | Profile | |
Lyndsey Scull | Director Communications | Profile | |
Kristen Stants | Chief Officer | Profile |
About Magenta Therapeutics Management Performance
The success or failure of an entity such as Magenta Therapeutics often depends on how effective the management is. Magenta Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Magenta management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Magenta management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Magenta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 66 people.
Please note, the presentation of Magenta Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Magenta Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Magenta Therapeutics' management manipulating its earnings.
Magenta Therapeutics Workforce Analysis
Traditionally, organizations such as Magenta Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Magenta Therapeutics within its industry.Magenta Therapeutics Manpower Efficiency
Return on Magenta Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.1M | |
Net Loss Per Executive | 8.5M | |
Working Capital Per Employee | 1.5M | |
Working Capital Per Executive | 11.2M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Magenta Stock
If you are still planning to invest in Magenta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Magenta Therapeutics' history and understand the potential risks before investing.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |